Evidence map›Paper›PMID 15841215›Full record

ArticleThe Journal of clinical investigation2005

Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.

Kazunori Nagashima, Carlos Lopez, Daniel Donovan, Colleen Ngai, Nelson Fontanez, André Bensadoun, Jamila Fruchart-Najib, Steve Holleran, Jeffrey S Cohn, Rajasekhar Ramakrishnan and 1 more

Registry-linked trialOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06592209 (Body Electric), which is not on this map. Cited by 81 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 2 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06592209 nacompletednot on this mapstarted 2023, after this paper: background citation

Body Electric: a Pragmatic Trial Evaluating Movement Breaks As a Public Health Strategy to Mitigate the Harms of Prolonged Sedentary Behavior

TypeinterventionalSponsorColumbia UniversityRan2023 to 2023Enrolled20,217ConditionsSedentary BehaviorArmsSedentary Breaks
3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 2 syntheses or guidelines pooled it, 177 citations in OpenAlex.

  1. Pioglitazone for type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2006 · on this map
    Pooled it
  2. Impact of thiazolidenediones on serum lipoprotein levels.Current atherosclerosis reports · 2006
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Kazunori NagashimaDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA.
Carlos Lopez
Daniel Donovan
Colleen Ngai
Nelson Fontanez
André Bensadoun
Jamila Fruchart-Najib
Steve Holleran
Jeffrey S Cohn
Rajasekhar Ramakrishnan
Henry N Ginsberg
Columbia University · USPediatrics and Genetics · USCornell University · USInserm · FRMontreal Clinical Research Institute · CA

Funding

ZOLEDRONIC ACID IN PROSTATE CANCERM01RR000645 · NCRR · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI COLTEN, HARVEY R · 1985 to 2006
$27.0M
NCRR NIH HHS M01 RR000645NCRR NIH HHS RR00645NHLBI NIH HHS HL 55368
6 · The paper itself

Abstract

Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and apoB. Lipoprotein lipase-mediated (LPL-mediated) lipolysis of VLDL TGs may also be reduced in T2DM if the level of LPL is decreased and/or the level of plasma apoC-III, an inhibitor of LPL-mediated lipolysis, is increased. We studied the effects of pioglitazone (Pio), a PPARgamma agonist that improves insulin sensitivity, on lipoprotein metabolism in patients with T2DM. Pio treatment reduced TG levels by increasing the fractional clearance rate (FCR) of VLDL TGs from the circulation, without changing direct removal of VLDL particles. This indicated increased lipolysis of VLDL TGs during Pio treatment, a mechanism supported by our finding of increased plasma LPL mass and decreased levels of plasma apoC-III. Lower apoC-III levels were due to reduced apoC-III PRs. We saw no effects of Pio on the PR of either VLDL TG or VLDL apoB. Thus, Pio, a PPARgamma agonist, reduced VLDL TG levels by increasing LPL mass and inhibiting apoC-III PR. These 2 changes were associated with an increased FCR of VLDL TGs, almost certainly due to increased LPL-mediated lipolysis.

Indexed as

AdiponectinAdultAgedBlood GlucoseCholesterol, HDLDiabetes Mellitus, Type 2Fatty AcidsFemaleHumansHypoglycemic AgentsInsulinIntercellular Signaling Peptides and ProteinsLipoproteinsMaleMiddle AgedPioglitazoneAdiponectinBlood GlucoseCholesterol, HDLFatty AcidsHypoglycemic AgentsInsulinIntercellular Signaling Peptides and ProteinsLipoproteinsPioglitazonePPAR gammaThiazolidinedionesTriglycerides

Identifiers

PMID15841215
PMCPMC1070635
OpenAlexW2132525699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.